Brilacidin performed excellent in our IPIX human trial for the treatment of acute bacterial skin and skin structure infections. One IV treatment was all that was needed for B to pierce the bacterial wall and kill the disease. MOA is the same... piercing the viral wall. Yes trial could fail, be mediocre or be a huge success. I like to think our absssi trial is a indicator of success. We shall soon see.